Ascendis Pharma A/S (ASND) Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares.
View ASND analyst ratings or view top-rated stocks.

11 brokers have issued 12 month price targets for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $92.00 to $187.00. On average, they expect the company's share price to reach $148.09 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for ASND or view top-rated stocks among Wall Street analysts.

Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 25.2% and is now trading at $91.30.
View the best growth stocks for 2023 here.

Ascendis Pharma A/S saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,430,000 shares, an increase of 13.6% from the April 30th total of 3,900,000 shares. Based on an average trading volume of 806,600 shares, the short-interest ratio is currently 5.5 days.
View Ascendis Pharma A/S's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our ASND earnings forecast.

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Thursday, April, 27th. The biotechnology company reported ($2.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.84) by $0.72. The biotechnology company had revenue of $36.04 million for the quarter, compared to analysts' expectations of $24.53 million. Ascendis Pharma A/S had a negative trailing twelve-month return on equity of 150.65% and a negative net margin of 721.72%.

ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), American CenturyFocused Dynamic Growth ETF (FDG), Global X Guru Index ETF (GURU), First Trust NASDAQ BuyWrite Income ETF (FTQI), Harbor Disruptive Innovation ETF (INNO) and Putnam Sustainable Future ETF (PFUT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (11.94%), FMR LLC (8.99%), Price T Rowe Associates Inc. MD (5.88%), Avoro Capital Advisors LLC (5.80%), Westfield Capital Management Co. LP (5.49%) and Wellington Management Group LLP (5.12%).

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASND stock can currently be purchased for approximately $91.30.

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.23 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($10.49) on an earnings per share basis.

The company employs 639 workers across the globe.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.